Page last updated: 2024-12-10

obtusifolin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

obtusifolin: isolated from Cassia obtusifolia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CassiagenusA plant genus of the family FABACEAE. Many species of this genus, including the medicinal C. senna and C. angustifolia, have been reclassified into the Senna genus (SENNA PLANT) and some to CHAMAECRISTA.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID3083575
CHEMBL ID448400
CHEBI ID80880
SCHEMBL ID3171011
MeSH IDM0543105

Synonyms (25)

Synonym
obtusifolin
477-85-0
C17039
CHEMBL448400
chebi:80880 ,
2,8-dihydroxy-1-methoxy-3-methylanthracene-9,10-dione
obtusifolin (anthraquinone)
2,8-dihydroxy-1-methoxy-3-methyl-9,10-anthracenedione
anthraquinone, 2,8-dihydroxy-1-methoxy-3-methyl-
9,10-anthracenedione, 2,8-dihydroxy-1-methoxy-3-methyl-
S9198
SCHEMBL3171011
DTXSID70197254
2,8-dihydroxy-1-methoxy-3-methylanthraquinone
AKOS037514758
Q27151380
HY-N2098
mfcd18452296
A14672
CCG-267293
FT-0775673
CS-0018619
MS-24039
XO171108
2,8-dihydroxy-1-methoxy-3-methyl-9,10-dihydroanthracene-9,10-dione

Research Excerpts

Overview

Oblusifolin is an anthraquinone‑based compound with antioxidant activity. It is obtained from the seeds of Cassia obtusifolia.

ExcerptReferenceRelevance
"Obtusifolin, which is an anthraquinone‑based compound with antioxidant activity, is obtained from the seeds of Cassia obtusifolia."( Obtusifolin inhibits high glucose‑induced mitochondrial apoptosis in human umbilical vein endothelial cells.
Liu, YF; Sheng, GT; Tang, Y; Zhong, ZY, 2018
)
2.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID343963Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID343959Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID1256630Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation at 50 uM by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID343961Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID343958Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID343960Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID1594062Inhibition of baker's yeast alpha-glucosidase using PNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins
AID1594063Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.25)18.7374
1990's0 (0.00)18.2507
2000's2 (12.50)29.6817
2010's12 (75.00)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.90 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]